- 4.4Impact Factor
- 8.8CiteScore
- 21 daysTime to First Decision
Special Issues
Cancers publishes Special Issues to create collections of papers on specific topics, with the aim of building a community of authors and readers to discuss the latest research and develop new ideas and research directions. Special Issues are led by Guest Editors, who are experts on the topic and all Special Issue submissions follow MDPI's standard editorial process.
The journal’s Editor-in-Chief and/or designated Editorial Board Member will oversee Guest Editor appointments and Special Issue proposals, checking their content for relevance and ensuring the suitability of the material for the journal. The papers published in a Special Issue will be collected and displayed on a dedicated page of the journal’s website. Further information on MDPI's Special Issue polices and Guest Editor responsibilities can be found here. For any inquiries related to a Special Issue, please contact the Editorial Office.
Advances in Dermato-Oncology
Deadline: 31 July 2026
Perioperative and Adjuvant Immunotherapy in Lung Cancer: New Strategies, Biomarkers, Patient Selection and Toxicity Management
Deadline: 31 July 2026
The Molecular Biology of Cholangiocarcinoma
Deadline: 31 July 2026
Cancer Metastasis in 2025–2026
Deadline: 31 July 2026
Advances in Electroporation-Based Technologies for Cancer Treatment
Deadline: 31 July 2026
Oncological Healthcare: Emergency and Supportive/Palliative Approaches
Deadline: 31 July 2026
New Trends in Urologic Oncology: Surgical Treatments, Robotics, Biomarkers, Diagnostic Tools, and Innovative Therapies
Deadline: 31 July 2026
Artificial Intelligence in Radiation Therapy for Head and Neck Cancers: Prediction, Personalization, and Precision
Deadline: 31 July 2026
Mitochondrial Metabolism and Cancer
Deadline: 31 July 2026
Disparities in Cancer Care: Advancing Equity Across the Cancer Continuum
Deadline: 31 July 2026
Multiple Myeloma and Immunology: From Pathophysiology to Therapy
Deadline: 31 July 2026
Multi-Omics Approaches to Tumor Antigen Discovery and Immunotherapy Target Identification
Deadline: 31 July 2026
of 261

